X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

By Brian Newell  |    May 31, 2022
In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...   Read More

Report finds PBMs are increasingly restricting patient access to medicines

By Brian Newell  |    May 25, 2022
More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

Annual projections from NHE compared to actual health care spending

By Katie Koziara  |    May 5, 2022
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...   Read More

What’s really happening when it comes to prescription drug costs

By Katie Koziara  |    April 27, 2022
New data show how robust competition continues to keep national spending on life-saving medicines in check, even as new innovative treatments reach patients. According to the latest report by the...   Read More

New analysis confirms hospitals markup prices for oncology therapies

By Gabby Migliara  |    April 21, 2022
A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...   Read More

Analysis: States can help patients save nearly $1,000 annually on their medicines

By Reid Porter  |    April 21, 2022
According to a new Ipsos/PhRMA poll, most Americans — 82% — agree that lowering out-of-pocket costs for health care should be a top priority for policymakers. A good place to start in lowering these...   Read More

How standardized plans can improve patients’ access to medicines

By Emilie Signora  |    April 18, 2022
While insurers negotiate steep discounts on medicines, they don’t always share these savings directly with patients. In recent years, insurers have shifted costs for brand medicines to patients by...   Read More

Correcting the record: Putting medicine costs and spending in context

By Nicole Longo  |    March 24, 2022
Last week, the Senate Finance Committee held a hearing focused on drug prices where the discussion was filled with misleading claims. We agree too many Americans struggle to afford their medicines,...   Read More

Sharing rebates can save Americans with diabetes $500 each year and improve adherence, especially for Black and Hispanic Americans

By Katie Koziara  |    March 16, 2022
A new study by GlobalData looked at brand oral antidiabetic drugs (OADs) and found that sharing negotiated rebates with patients in commercial health plans at the pharmacy counter can help lower...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates